Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002962 (angina)
 21,142 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An observation of malignant mesothelioma of the pericardium is described. The tumour grew as papillomatous formations and thick plaques lining the inner surface of the pericardium with transition to the epicardium and the development of massive hemorrhagic pericarditis. The mixed nodular-plate form is histological close to adenocarcinoma. There were metastases in the pleura, paratracheal and posterior mediastinal lymph nodes. Clinically the disease ran a course with angina pectoris and simulated idiopathic myocarditis not confirmed histologically.
 ...
PMID:[Malignant mesothelioma of the pericardium]. 72 68

A 64-year-old lung cancer patient combined with angina pectoris was admitted to our hospital. Chest roentgenogram showed a coin lesion in the left upper lobe. Broncho-fiberscopic examination proved adenocarcinoma. Coronary angiography revealed 90% stenosis of the left circumflex artery. Percutaneous transluminal coronary angioplasty (PTCA) was done and resulted in success. Eight days after PTCA, left upper lobectomy for lung cancer was undergone. Postoperative course was uneventful. Compared with coronary artery bypass grafting, PTCA was very useful for the patient having malignant disease combined with angina pectoris because of little surgical stress and no delay of operation.
 ...
PMID:[A case of an operation for lung cancer after PTCA]. 223 93

A 50-year-old woman who developed severe angina pectoris 67 months following radiation therapy of the left side of the chest for adenocarcinoma of the left breast is reported. Angiographic studies showed an isolated severe stenosis in the left anterior descending coronary artery. Successful percutaneous transluminal coronary angioplasty was performed.
 ...
PMID:Percutaneous transluminal coronary angioplasty for coronary stenosis following radiotherapy. 296 70

A prospective phase II study was conducted to determine the response, toxicity and survival rate of lung cancer patients treated with combination paclitaxel and carboplatin in stage IIIB and IV NSCLC. Eligible patients required measurable and/or evaluable diseases; performance status (ECOG) 0-2; no previous chemotherapy; adequate hepatic, renal and bone marrow function. Paclitaxel was administered at a dose of 200 mg/m2, 3 h infusion, followed by carboplatin at an AUC of 6. Treatment was repeated every 3 weeks for six courses. G-CSF 5 microgram/kg was subcutaneously injected during subsequent courses if there was grade 3-4 leucopenia or granulocytopenia in the previous course. From April 1996 through July 1997, 53 patients were enrolled; all are assessable for toxicity and response. The median age was 56 years (range, 20-77 years). Sixty four percent were male, 64% had adenocarcinoma and 62% had stage IV disease. Two hundred and seventy two courses were administered; 36 patients (68%) completed all six cycles. Two patients achieved a complete response (4%) and 27 patients achieved a partial response (51%), for an overall response rate of 55%. Sixteen patients had stable disease (30%) and 8 patients had progressive disease (15%). The median progression free survival time for all patients, stage IIIB and stage IV patients was 28 weeks (range, 18-37 weeks), 31 weeks (range 21-41 weeks) and 22 weeks (range 16-29 weeks), respectively. The median survival time and 1 year survival rate for all patients was 55 weeks (range, 51-59 weeks) and 55%, respectively. Stage IIIB patients had better median survival time and 1-year survival rate than stage IV patients (75 vs. 46 weeks, P = 0.007; 80% vs. 42%, P = 0.003). Grade 3 and 4 granulocytopenia, anemia and thrombocytopenia were observed in 25, 3, and 1%, respectively, of the 272 courses administered. G-CSF was required in 28% of the 272 courses. There were four episodes of febrile neutropenia (1.5%), three episodes of angina pectoris (1%) and one episode of anaphylaxis (0.4%). Other common toxicities, generally mild, included myalgia, arthralgia, peripheral neuropathy and asthenia. Most toxicities showed cumulative effect. Paclitaxel plus carboplatin is a moderately active regimen in advanced NSCLC. Toxicities of this regimen are well tolerated.
 ...
PMID:Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. 1059 28

A rare case of hemorrhagic gastric carcinoma in an acromegalic patient is reported. A 79-year-old Japanese man was referred to our hospital with diagnoses of upper gastrointestinal hemorrhage and angina pectoris. This patient showed typical clinical features of acromegaly, with increased serum growth hormone (GH) and insulin-like growth factor I (IGF-I) level. A high titer of serum anti-Helicobacter pylori (H. pylori) IgG was also observed. After percutaneous transluminal coronary angioplasty treatment for stenosis of the right coronary artery, the patient underwent distal gastrectomy. Gastric cancer was Type 2 macroscopically and was diagnosed histologically as a papillary and well to moderately differentiated tubular adenocarcinoma. Reverse transcription-polymerase chain reaction analysis estimated that the amount of IGF-I receptor mRNA expression in the gastric cancer tissue was 1.6 times higher than that in the adjacent atrophic mucosa, whereas the amount of IGF-I mRNA expression in the cancer tissue was only half that in the atrophic mucosa. Both the stimulatory effects of GH and/or IGF-I on cell proliferation and H. pylori infection in gastric tumorigenesis may have been responsible for the development and growth of gastric carcinoma in this patient.
 ...
PMID:Hemorrhagic gastric carcinoma in an acromegalic patient. 1140 75

Among the various pathophysiologic mechanisms proposed to explain the 5-fluorouracil cardiotoxicity, coronary vasospasm, occurring most frequently after the completion of the second or third dose of the cycle, has gained wide acceptance. We describe what to our knowledge is the first observation of typical Prinzmetal variant angina occurring very early after having started a 5-fluorouracil infusion administered as a chemotherapy regimen to a 66-year-old man with an adenocarcinoma of the right colon.
 ...
PMID:Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy. 1456 86

Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which is converted in tumor cells to 5-FU by the enzyme thymidine phosphorylase. Nowadays, it is being widely used into the management of colorectal, breast and head and neck cancers because of its oral route and its comparable efficacy with 5-FU. 5-FU induced cardiotoxicity (angina and myocardial infarction) has been reported the literature, but capecitabine induced cardiotoxicity is less reported event. We report a patient with diagnosis of locally advanced adenocarcinoma of rectum who developed symptomatic bradycardia and acute ischemia while receiving oral capecitabine 825mg/m(2) twice daily with preoperative radiation.
 ...
PMID:Capecitabine induced cardiotoxicity: a case report and review of literature. 2218 41

We encountered a rare case of an adenocarcinoma and basaloid squamous cell carcinoma in the same lung lobe. The patient was a 66-year-old female. During the observation of the course of angina pectoris, chest computed tomography( CT) showed a nodular shadow in the right upper lung field and a club like lesion dorsal to this shadow. Since the former lesion was diagnosed as an adenocarcinoma, right upper lobectomy and lymph node dissection were performed. The latter lesion was diagnosed as a basaloid squamous cell carcinoma by pathology. Basaloid squamous cell carcinoma is a relatively rare tumor associated with a poor prognosis that is classified as a subtype of squamous cell carcinoma. There have been no reported cases of this tumor developing concurrently with adenocarcinoma. Since there were no histological transition images, and immunostaining findings completely differed between the 2 tumors, these tumors may have incidentally developed during the same period in the same lung lobe.
 ...
PMID:[Adenocarcinoma and basaloid squamous cell carcinoma in the same lung lobe]. 2474 29

We report a 57-year-old patient with acute anterior wall infarction with a history of a coronary baypass graft operation in 2007. He also had concurrent left arm cyanosis and severe pain. He had received diagnosis of pancreatic adenocarcinoma one month previously and had had his first chemotherapy in the previous week with gemcitabine and 5-fluorouracil. After the angiography, a giant thrombus was detected in the proximal left subclavian artery, deteriorating the flows of both left internal mammarian artery (LIMA) to left anterior descending (LAD) coronary artery graft, as well as the left brachial artery. The proximal subclavian artery was stented and good flow was achieved. Through the LIMA, the distal part of LAD, which was totally obstructed with probable distal thrombus embolization, was reached and a percutaneous balloon angioplasty performed. However, the no-reflow phenomenon was observed in distal LAD. A Fogarty traction of thrombus was performed successfully for the revascularization of the left arm. Approximately 30 minutes after the procedure, both angina and ST segment elevation in ECG were resolved under unfractioned heparin and nitroglycerin infusion. However, the patient died due to sepsis seven days after admission to hospital. In the literature, there are only a few previous reports on this rare clinical entity. The eitology, presentation, and the possible management strategies of this clinical entity is presented in this report.
...
PMID:Management of a subclavian artery thrombosis causing acute anterior wall infarction and concurrent left arm ischemia in a patient with prior coronary bypass. 2562 Mar 37

the epidermal growth-factor receptor (EGFR) and its signaling pathway have become a major target for therapy of non-small cell lung cancer (NSCLC). After the BR.21 study showed its effectiveness and its tolerability in older patients, erlotinib, a specific EGFR tyrosine-kinase inhibitor, has been approved for NSCLC therapy after failure of treatment with at least one line of chemotherapy (CT). The authors present the case of a 63 years-old female patient, with a history of angina pectoris, who was diagnosed with a lung adenocarcinoma. Because of poor tolerance to first-line CT, she had second-line treatment with erlotinib. There was a good response to therapy, along with symptomatic improvement. Adverse effects were light to moderate, well tolerated, and required no dose reduction. Rev Port Pneumol 2008; XIV (Supl 3): S17-S22.
...
PMID:Erlotinib in second-line therapy for non-small cell lung cancer - A clinical case. 2596 82


1 2 Next >>